Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Obesity Has Little Impact On Older COVID-19 Patients With Type 2 Diabetes
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Jacqueline A.
Received at Testimonial Submit Form Thursday, Aug 13, 2020, 6:53 AM PDT
(Unedited)

Hi my name is Jacqueline. I started taking EZorb two years ago when I was diagnosed for osteoporosis in my spine and osteopenia in my left hip.

I just had a bone scan done and results came back Yesterday. I had a 5.7% increase in the lumbar spine and 1.6% increase in the hip.

This means I no longer have osteoporosis in the spine. With all the terrible things going on in our society, I couldn't be more grateful.

I've been taking EZorb diligently and I plan on staying on it forever. Love this product and have told all of my friends. Many are now your customers.

Thank you for making this wonderful product available.

Letter II: From Terri S.
Received at sharesuccess @ ezorbonline.com Friday, May 1, 2020, 3:13 PM PDT
(Unedited)

I just wanted to give you all a heads up. I did a 3 month study/program with my husband as the guinea pig, to reduce his neck pain caused by a bone spur which the docs would not remove.

I will be posting our positive results to a facebook group next week, which may result in a bunch of orders for EZorb, from different parts of the world.

I am ordering mine in advance, so as not to have any delays in my shipments. This group specifically is facing bone spurs/issues associated with DISH.

Thank you.

This newsletter is now read by over 120,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public.

Obesity is a significant predictor of poor COVID-19 outcomes in patients who also have type 2 diabetes, but only in those up to the age of 75 years, report French researchers.

A previous interim analysis of the French multicenter CORONADO study identified obesity as the only preadmission factor with a significant bearing on the outcomes of people with type 2 diabetes who are hospitalized with COVID-19.

But this latest analysis involving 1965 patients shows that the effect of obesity varies according to age.

“The deleterious impact of obesity on COVID-19 prognosis seems to be much less pronounced in the elderly and advanced age by itself must be considered as a major risk for severe COVID-19 outcomes in all people with type 2 diabetes, irrespective of BMI status,” say the researchers.

The study participants were admitted to 68 French hospitals between March and April 2020. The primary outcome was death or need for invasive mechanical ventilation by day 7 of hospitalization; the individual components occurred in 9.7% and 19.6% of patients, respectively.

For patients younger than 75 years, having a BMI of 25.0-29.9 kg/m² was not significantly associated with the risk for the primary outcome relative to having a lower BMI, but having a BMI of 30.0 kg/m2 or higher increased the risk a significant 2.32-fold.

By contrast, there was no significant association between BMI and the primary outcome among patients who were aged 75 years or older, report co-lead researchers Pierre Gourdy (Hopital Rangueil, Toulouse) and Bertrand Cariou (Hopital Guillaume et Rene Laennec, Nantes) and team. These findings were adjusted for factors including sex, smoking status, cardiovascular disease, hypertension, and antidiabetes medications.

Nearly 80% of the cohort as a whole was overweight or obese, and the team found a graded association between WHO BMI category and risk for the primary outcome, which was driven by risk for mechanical ventilation.

Patients who were aged 75 years or older were however much less likely to require mechanical ventilation by day 7 than younger patients were, at rates of around 5-15% versus 20-30%, although they were more likely to die, at approximately 20% versus 3-10%.

The researchers say their finding of a different response in the oldest age group of COVID-19 patients with type 2 diabetes is in line with previous research.

“Altogether, this reinforces the need for a specific clinical management and dedicated trials in elderly people affected by COVID-19,” they write in Diabetes, Obesity and Metabolism.

Original research was published in Diabetes Obes Metab 2020 ; doi:10.1111/dom.14228.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index